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Summary
CDC and the U.S. Food and Drug Administration rely on state and local health departments, health-care providers, and the
public to report the occurrence of adverse events after vaccination to the Vaccine Adverse Event Reporting System. With such data,
trends can be accurately monitored, unusual occurrences of adverse events can be detected, and the safety of vaccination interven-
tion activities can be evaluated.
On January 24, 2003, the U.S. Department of Health and Human Services (DHHS) implemented a preparedness program in
which smallpox (vaccinia) vaccine was administered to federal, state, and local volunteers who might be first responders during a
biologic terrorism event. As part of the DHHS Smallpox Preparedness and Response Program, CDC in consultation with experts,
established surveillance case definitions for adverse events after smallpox vaccination. Adverse reactions after smallpox vaccina-
tion identified during the 1960s surveillance activities were classified on the basis of clinical description and included eczema
vaccinatum; fetal vaccinia; generalized vaccinia; accidental autoinoculation, nonocular; ocular vaccinia; progressive vaccinia;
erythema multiforme major; postvaccinial encephalitis or encephalomyelitis; and pyogenic infection of the vaccination site.
This report provides uniform criteria used for the surveillance case definition and classification for these previously recognized
adverse reactions used during the DHHS Smallpox Preparedness and Response Program. Inadvertent inoculation was changed to
more precisely describe this event as inadvertent autoinoculation and contact transmission, nonocular and ocular vaccinia.
Pyogenic infection also was renamed superinfection of the vaccination site or regional lymph nodes. Finally, case definitions were
developed for a new cardiac adverse reaction (myo/pericarditis) and for a cardiac adverse event (dilated cardiomyopathy) and are
included in this report. The smallpox vaccine surveillance case definitions presented in the report can be used in future vaccina-
tion programs to ensure uniform reporting guidelines and case classification.
Introduction
Surveillance guidelines that include standardized case defi-
nitions for reporting of notifiable infectious diseases are im-
portant public health tools that contribute to the assessment
of disease trends, measurement of intervention effectiveness,
and detection of disease outbreaks (1). Comparable surveil-
lance guidelines for the classification and reporting of adverse
reactions after vaccination are nominal and have not com-
monly include standardized case definitions (2,3). The term
vaccine-related “complication” is often used interchangeably
with the terms “side effects” or “adverse reaction” and should
be distinguished from the term “adverse event.” An adverse
reaction is an untoward effect that occurs after a vaccination
and is extraneous to the vaccine’s primary purpose of produc-
ing immunity (e.g., eczema vaccinatum). Adverse reactions
have been demonstrated to be caused by the vaccination. In
contrast, adverse events are untoward effects observed or re-
ported after vaccinations, but a causal relation between the
two have yet to be established. This report focuses on adverse
reactions known to be caused by smallpox vaccine (with the
exception of dilated cardiomyopathy that has not been shown
to have a causal relation) on the basis of scientific evidence.
Uniform criteria for classification of adverse reaction reports
The material in this report originated in the National Immunization
Program, Anne Schuchat, MD, Director.
Corresponding preparer: Christine Casey, Immunization Safety
Office, Office of the Chief of Science, 1600 Clifton Road, NE, MS
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after smallpox (vaccinia) vaccination have been established.
Criteria for dilated cardiomyopathy, an adverse event (not
shown to have a causal relation with smallpox vaccination),
also have been established. These case definitions and report-
ing guidelines were used by CDC and the Office of the Assis-
tant Secretary of Defense for Health Affairs during the
mandatory Department of Defense (DoD) and voluntary U.S.
DHHS smallpox vaccination programs that were designed to
increase national preparedness in the event of a biologic ter-
rorism attack (4–6).
Adverse reactions caused by smallpox vaccination range from
mild and self-limited to severe and life-threatening. During
the recent smallpox vaccination programs, CDC, DoD, and
the joint Advisory Committee on Immunization Practices
(ACIP)-Armed Forces Epidemiological Board (AFEB) Small-
pox Vaccine Safety Working Group (SVS WG) relied on sur-
veillance data from the smallpox pre-eradication era to estimate
frequencies of adverse reactions expected during these vacci-
nation programs. These estimates might be limited because
the targeted population during the 1960s was mostly chil-
dren who had never been previously vaccinated; the recent
program targeted healthy adults, some of whom had received
smallpox vaccines (6). Furthermore, adverse reactions during
the 1960s were classified and reported by providers on the
basis of subjective clinical diagnosis, and standard collection
or analytical tools were not applied to the clinical data (7–
11). Without explicit criteria for identifying cases for public
health surveillance, state health departments and individual
practitioners often apply different criteria for reporting simi-
lar cases (1). Surveillance data for adverse reactions after small-
pox vaccination must be aggressively pursued and standardized
to assess accurately the frequency of adverse events after small-
pox vaccination.
This report describes the case definitions used to classify
reported adverse events during the DHHS smallpox vaccina-
tion program. The overall safety surveillance system and re-
lated findings are reported elsewhere (12).
Reporting Guidelines
These surveillance case definitions establish reporting crite-
ria for prospective or retrospective classification of cases. Clini-
cal, laboratory, and epidemiologic information are necessary
for accurate case classification, which could not be obtained
without cooperation and information exchange between treat-
ing health-care providers, state health officials, laboratorians,
and CDC. Any adverse event after smallpox vaccination should
be reported to state health departments and the Vaccine Ad-
verse Events Reporting System (VAERS), particularly those
events known to be adverse reactions (Table 1). Any adverse
reaction that requires treatment with vaccine  immune globu-
lin (VIG) or cidofovir should be reported immediately, and
adverse events that meet the regulatory criteria for “serious”
(i.e., those resulting in hospitalization, permanent disability,
life-threatening illness, or death) (13) should be reported
within 48 hours; all other events should be reported within 1
week (14). Reports can be submitted to VAERS at http://
www.vaers.hhs.gov, 877-721-0366, or P.O. Box 1100,
Rockville, MD 20849-1100. Report forms and assistance with
reporting are available from VAERS (800-822-7967).
Case Definition and Classification
ACIP-AFEB SVS WG was responsible for safety oversight
of the DHHS and DoD smallpox preparedness programs. The
majority of the case definitions for vaccinia adverse reactions
were drafted by the Vaccinia Case Definition Development
working group in collaboration with ACIP-AFEB SVS WG.
The Vaccinia Case Definition Development working group
membership included CDC and DoD medical epidemiolo-
gists, smallpox eradication experts, ophthalmologists, derma-
tologists, cardiologists, and infectious-disease specialists. These
work groups contributed to the development of case defini-
tions by completing literature searches, translating publica-
tions, coordinating or participating in meetings, collecting or
analyzing data, investigating cases, providing subject-matter
expertise, and drafting and revising case definitions. The case
definition for fetal vaccinia was developed by CDC and DoD
for use in the development of the National Smallpox Vaccine
in Pregnancy Registry (15).
For all cases, exposure to vaccinia is required; vaccination,
close contact with a recent vaccinee, or intrauterine exposure
TABLE 1. Adverse events after smallpox vaccination that are
recommended to be reported to the Vaccine Adverse Event
Reporting System and to state health departments*







Erythema multiforme major or Stevens-Johnson Syndrome§
Fetal vaccinia
Postvaccinial central nervous system disease
Myo/pericarditis
Dilated cardiomyopathy¶
* Any adverse event that is of concern to the clinician or patient should be
reported.
† Previously referred to as pyogenic infection of vaccination site.
§ Clinically defined.
¶ Causal association with smallpox vaccination has not been shown.
Vol. 55 / RR-1 Recommendations and Reports 3
can fulfill this criterion. Vaccinia virus can be transmitted from
the vaccination site to close contacts of persons who received
smallpox vaccine, and these contacts can experience the same
adverse reactions as vaccinees.
Smallpox vaccine adverse events can be divided into several
categories. Localized reactions include a superinfection of the
vaccination site or regional lymph nodes and robust take (RT).
Unintentional transfer of vaccinia virus includes transfer from
the vaccination site to elsewhere on the vaccinee’s body and is
called inadvertent autoinoculation.  When the virus is trans-
ferred from the vaccinee to a close contact, it is called contact
transmission. In either case, if the virus is transferred to the
eye and surrounding orbit, it is referred to as ocular vaccinia.
Diffuse dermatologic complications include two groups. The
first group (hypersensitivity rashes) includes nonspecific, post-
vaccination rash, erythema multiforme minor, and Stevens-
Johnson syndrome. These lesions are not thought to contain
vaccinia virus, and because these terms are defined elsewhere
in the dermatologic literature, they not included in this re-
port. The second group of diffuse dermatologic complications
is thought to be caused by replicating vaccinia virus that can
be recovered from the rash of generalized vaccinia (GV) (usu-
ally a benign, self-limiting condition), eczema vaccinatum (EV)
(often associated with substantial morbidity), and progressive
vaccinia (PV) (which is generally fatal). Rare adverse reac-
tions include fetal vaccinia and postvaccinial central nervous
system diseases such as post-vaccinial encephalitis or encepha-
lomyelitis. Other reactions previously reported but not well
described include the newly characterized cardiac adverse re-
action, myo/pericarditis (M/P) or the newly described car-
diac adverse event dilated cardiomyopathy (DCM), which has
not been yet been demonstrated to be etiologically linked.
Localized Reactions
Superinfection of the Vaccination Site or
Regional Lymph Nodes
Vaccination progression and normal local reactions are dif-
ficult to distinguish from a superinfection of the vaccination
site or regional lymph nodes. Secondary infections (i.e., su-
perinfections) of the vaccination site are uncommon (rate: 0.55
per 10,000 vacinees) (16) and are typically mild to moderate
in clinical severity (Box 1). Persons at greatest risk are chil-
dren and those who frequently manipulate and contaminate
the vaccination site. Occlusive dressings might lead to mac-
eration and increased risk for infection. Secondary strepto-
coccal bacterial infection has been reported (9), but anaerobic
organisms and mixed infections also might be expected.
Distinguishing superinfection of the vaccination site or re-
gional lymph nodes can be particularly challenging because
both a bacterial cellulitis and a variant of the normal major
reaction or RT have similar signs and symptoms.
Robust Take
An RT is a vaccinial cellulitis and is defined as >3 inches
(7.5 cm) of redness with swelling, pain, and warmth at the
vaccination site. These symptoms peak on days 6–12 postvac-
cination and regress within the following 24–72 hours. RTs
can occur in up to 16% of smallpox vaccinees (16,17). Sus-
pected bacterial cellulitis after smallpox vaccination is often
treated empirically with antibiotics without a period of obser-
vation, and bacterial or other cultures are rarely obtained. As
clinicians have gained experience with smallpox vaccination,
some have ceased treating empirically with antibiotics in fa-
vor of close observation. Clinical observations suggest that
the majority of vaccinees’ local symptoms resolved without
intervention, leading providers to conclude that these cases
were RTs (CDC, unpublished data, 2002). In contrast to an
RT, superinfections refer to cellulitis caused by agents other
than vaccinia.
Unintentional Transfer of Vaccinia Virus
Inadvertent Autoinoculation
Unintentional transfer of vaccinia virus includes transfer
from the vaccination site (or probable site of inoculation in a
person infected with vaccinia through contract transmission)
to elsewhere on the vaccinee’s (or contact’s) body, which is
called inadvertent autoinoculation (Box 2). Smallpox vaccinees
or contacts can transfer vaccinia virus to their hands or fo-
mites, which becomes a source for infection elsewhere on the
body. The most common nonocular sites are the face, nose,
mouth, lips, genitalia, and anus. Lesions at autoinoculation
sites progress through the same stages (e.g., papular, vesicular,
pustular, crusting, and scab) as the vaccination site. When
autoinoculation occurs >5 days postvaccination, the develop-
ing immune response might attenuate the lesions and their
progression. Persons at highest risk for inadvertent autoin-
oculation are children aged 1–4 years and those with disrup-
tion of the epidermis, including but not limited to abrasions
and burns (17).
Contact Transmission
When the virus is transferred from the vaccinee to a close
contact, this transmission is termed contact transmission. Per-
sons in close contact with a recent vaccinee or associated vec-
tors (e.g., distant lesions on a vaccinee resulting from
inadvertent autoinoculation, clothing, bedding, or bandages
contaminated by vaccinia) might acquire vaccinia infection.
Vaccinia virus is shed from the vaccination site or from dis-
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tant lesions caused by autoinoculation, GV, EV, or PV (Box
3). Viral shedding might occur until the scab detaches from
the vaccination site or distant lesions; virus can survive for
several days on clothing, bedding, or other fomites (18). Al-
though virus exists in the scab, it is bound in the fibrinous
matrix, and the scab is not thought to be highly infectious
(17). Infection acquired through contact transmission can re-
sult in the same adverse events observed after smallpox
vaccination.
Ocular Vaccinia
In the case of either contact transmission or inadvertent
autoinoculation, if the virus is transferred to the eye and sur-
rounding orbit, this transmission is referred to as ocular vac-
cinia. Ocular vaccinial infections result from the transfer of
vaccinia from the vaccine site or other lesion containing vac-
cinia to or near the eye. These infections account for the ma-
jority of inadvertent inoculations (11) (Box 4). Infections can
be clinically mild to severe and can lead to vision loss. When
suspected, ocular vaccinia infections should be evaluated with
a thorough eye examination, including use of a slit lamp. These
cases should be managed in consultation with an
ophthalmologist.
Diffuse Dermatologic Complications
Diffuse dermatologic complications include two groups. The
first includes erythema multiforme minor and Stevens-Johnson
syndrome, which are clinically defined elsewhere in the der-
Superinfection of the vaccination site or regional lymph
nodes is defined as a nonvaccinial superinfection (e.g., su-
perinfection caused by bacterial, fungal, atypical, or viral
organisms) that produces a local inflammatory response at
the site of vaccination and can present with the same signs
and symptoms as vaccinia virus replication at the vaccina-
tion site.
Case definition for superinfection of the vaccination
site or regional lymph nodes
A suspected case of superinfection of the vaccination
site or regional lymph nodes is defined by the following
criteria:
• vaccination site or regional lymph nodes with three or
more of the following findings:
— dolor (pain and/or tenderness),
— calor (warmth),
— rubor (redness), and
— other (regional lymphadenopathy; lymphangitic
streaking; edema, induration and/or swelling;




— onset or peak symptoms occur from day of vaccina-
tion to day 5 after vaccination and/or day 13–60 after
vaccination (excludes days 6–12 after vaccination);
and
• clinical course:
— clinical criteria persist or worsen for hours to days
after vaccination; patient report is adequate.
BOX 1. Surveillance case definition for superinfection of the vaccination site or regional lymph nodes after smallpox vaccination
for use in smallpox vaccine adverse event monitoring and response
A confirmed case of superinfection of the vaccination
site or regional lymph nodes is defined by the following
criteria:
• vaccination site or regional lymph nodes with three or
more of the following findings:
— dolor (pain and/or tenderness),
— calor (warmth),
— rubor (redness), and
— other (regional lymphadenopathy; lymphangitic
streaking; edema, induration and/or swelling;




— symptoms occur from day of vaccination to 60 days
after vaccination (inclusive);
and
• laboratory criteria having one or more of the following
findings:
— positive results of pathogenic culture (e.g., bacterial,
fungal, atypical, or nonvaccinial viral culture),
— positive microscopy results (e.g., Gram stain, silver
stain, acid-fast bacillus stain, or darkfield), and




— findings consistent with superinfection (e.g., lym-
phadenopathy or abscess) by magnetic resonance im-
aging, computed tomography scan, or ultrasound.
* Bioburden is referred to as the number of microorganisms on a contaminated object; it is also called bioload. For testing of vaccinia vaccine vial, a positive
bioburden test indicates that the accepted limits of bioload have been exceeded and the vaccine is not suitable for use.
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matologic literature (19,20), and other nonspecific postvacci-
nation rashes with lesions that are thought to be free of vac-
cinia virus. For surveillance purposes, clinical diagnosis is
adequate for case classification. The second group includes
adverse reactions thought to be caused by replicating vaccinia
virus recovered from skin lesions, which can be associated with
risk for autoinoculation or contact transmission (21).
Generalized Vaccinia
GV is a disseminated vesicular or pustular rash and is usu-
ally benign and self-limited among immunocompetent hosts
(Box 5). GV might be accompanied by fever and can produce
skin lesions anywhere on the body. GV also can appear as a
regional form that is characterized by extensive vesiculation
around the vaccination site or as an eruption localized to a
single body region (e.g., arm or leg). The skin lesions of GV
are thought to contain virus spread by the hematogenous route.
First-time vaccinees are at higher risk for GV than revaccinees
(22). GV is often more severe among persons with underly-
ing immunodeficiency who might have been inadvertently
vaccinated; these patients might benefit from early interven-
tion with VIG. GV should not be confused with multiple
inadvertent inoculations that might occur in the presence of
acute or chronic exfoliative, erosive, or blistering skin disease,
including Darier’s disease.* GV also should be differentiated
from EV, which typically occurs in persons with a history of
atopic dermatitis and is often associated with systemic illness.
Eczema Vaccinatum
Persons with a history of atopic dermatitis (i.e., eczema) are
at highest risk for EV (Box 6). Onset of the characteristic le-
sions can occur concurrently or shortly after the occurrence
of the reaction at the vaccination site. EV cases resulting from
Inadvertent autoinoculation occurs when a person who
has received smallpox vaccine or experienced inoculation
from contact might physically transfer vaccinia virus from
vaccination or contact site to another part of the body
through scratching or through inanimate objects such as
clothing, dressings, or bedding. The most common sites of
inadvertent autoinoculation, nonocular are the face, nose,
mouth, lips, genitalia, and anus. Lesions at autoinocula-
tion sites progress through the same papular, vesicular, and
pustular stages as the vaccination site. When autoinocula-
tion occurs more than 5 days postvaccination, the develop-
ing immune response might attenuate the lesions and their
progression. Persons at highest risk for inadvertent autoin-
oculation are children aged 1–4 years and those with dis-
ruption of the epidermis, including, but not limited to,
abrasions or burns.
Case definition for inadvertent autoinoculation
(nonocular)
A suspected case of inadvertent autoinoculation is de-
fined by the following criteria:
• affected person has been recently vaccinated and had
one or more lesions at one or more sites beyond the
boundaries of the dressing that was used. Lesions
progress morphologically through papule, vesicle, pus-
tule, and scab,* and
BOX 2. Surveillance case definition for inadvertent autoinoculation (nonocular) for use in smallpox vaccine adverse event
monitoring and response
• lesions appear up to 10 days after the period begin-
ning with initial vaccination or contact through final
resolution and scarring of lesions at vaccination or con-
tact inoculation site.
A probable case of inadvertent autoinoculation meets
the criteria for a suspected case and
• does not meet the case definition for generalized vac-
cinia*, eczema vaccinatum, or progressive vaccinia, and
• other likely etiologies (e.g., bacterial or viral infection)
have been excluded.
A confirmed case of inadvertent autoinoculation meets
the criteria for a suspected or probable case of inadvertent
autoinoculation and has the following laboratory evidence
of vaccinia infection (on the basis of testing skin lesions
distant from the vaccination site in a vaccinee):
• positive test results for vaccinia polymerase chain reac-
tion (PCR) assay or antigen detection techniques (e.g.,
direct fluorescent assay or direct fluorescent antibody),
or
• demonstration of vaccinia virus by culture.
Note: Histopathologic examination showing typical
orthopox cytopathic changes or electron microscopy of
biopsy specimens revealing orthopox virus are strongly sug-
gestive of infection with vaccinia and should be confirmed
by subsequent PCR or culture.
* Generalized vaccinia should be considered if >20 lesions are present.
* Darier’s disease is a rare, dominantly inherited, keratinizing skin disorder
characterized by innumerable crusts and epidermal fissures, most prominent
on seborrheic areas (e.g., behind ears and on neck and sternum). The clinical
manifestations, once evident, are lifelong but can wax and wane in severity.
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secondary transmission usually appear with skin eruptions
approximately 5–19 days after the suspected exposure. EV
lesions follow the same dermatologic course (Jennerian pro-
gression) as the vaccination site in a vaccinee, and confluent
or erosive lesions can occur. The rash is often accompanied by
fever and lymphadenopathy, and affected persons are fre-
quently systemically ill. EV tends to be most severe among
first-time vaccinees, unvaccinated close contacts of vaccinees,
and young children.
Early diagnosis of EV and administration of VIG is helpful
to reduce associated morbidity and mortality. Two thirds of
potential smallpox vaccinees failed to recall an exclusionary
dermatologic condition such as atopic dermatitis (eczema) in
themselves or their close contacts (23). Poor recall and incon-
sistent diagnosis of atopic dermatitis contributes to a chal-
lenging screening program to exclude persons at risk for EV
(24). Therefore, when evaluating vaccinees or close contacts
of recent vaccinees with a clinical presentation consistent with
EV, despite a negative self-reported history of atopic dermati-
tis or Darier’s disease, clinicians should consider EV and as-
sess for treatment with VIG.
Progressive Vaccinia
PV is rare, severe, and often fatal and results when a vacci-
nation site fails to heal and vaccinia virus replication persists.
The skin surrounding the vaccination site becomes vaccinia
infected, and secondary metastatic vaccinia lesions can occur
(Box 7). Lesions can appear necrotic, fungated, piled-up, or
well demarcated.  Concomitant bacterial superinfection also
can occur. PV typically occurs in persons with an underlying
humoral or cellular immune deficit. Management of PV should
include aggressive therapy with VIG or second line agent




Rarely, smallpox vaccination of a pregnant woman can re-
sult in fetal vaccinia (Box 8). Transmission to the fetus can
occur any time during pregnancy. The route of transmission
is unknown but is presumed to be through viremia. Abortion,
stillbirth, or live birth (usually premature followed by death)
or birth of a surviving but pox-scarred infant can occur after
the mother’s exposure to vaccinia. Fetal or newborn skin le-
sions have been described as macular, papular, vesicular, pus-
tular, or as scars or areas of epidermolysis (15).
Contact transmission of vaccinia virus occurs when
virus shed from smallpox vaccination sites or from dis-
tant lesions in persons with inadvertent autoinoculation,
generalized vaccinia (GV), eczema vaccinatum (EV), or
progressive vaccinia (PV) is transferred to another per-
son. Virus might be shed until the scab heals. The virus
can survive for several days on clothing, bedding, or other
inanimate surfaces. An unvaccinated or nonrecently vac-
cinated person in close contact (i.e., touching a person’s
lesions or vaccination site, clothing, bedding, or ban-
dages) with a vaccinee or their inanimate objects might
acquire vaccinia infection. Infection acquired through
contact transmission can result in inadvertent autoin-
oculation from the exposure site to additional sites (in-
cluding ocular vaccinia) or can result in other adverse
reactions.
Case definition for contact transmission
(nonocular)
A suspected case of contract transmission is defined as
• the development one or more lesions that progress
through papule, vesicle, or pustule stages;
• history of close contact with
— someone who has received the vaccine <3 weeks
before the exposure, or
— someone who has had autoinoculation GV, EV,
and PV diagnosed; and
• lesions appear 3–9 days after vaccinia exposure.
A probable case of contact transmission meets the
case definition for suspected case, and other likely
etiologies (e.g., bacterial or viral infection) have been
excluded.
For a confirmed case of contact transmission, labora-
tory evidence of vaccinia infection exists on the basis of
testing skin lesions in a close contact of a known vac-
cinee.  Laboratory evidence of vaccinia infection includes
• positive test results for vaccinia polymerase chain re-
action (PCR) assay or antigen detection techniques
(e.g., direct fluorescent antibody)
or
• demonstration of vaccinia virus by culture.
Note: Histopathologic examination showing typical
orthopox cytopathic changes or electron microscopy of
biopsy specimens revealing orthopox virus is strongly
suggestive of infection with vaccinia and should be con-
firmed by subsequent PCR or culture.
BOX 3. Surveillance case definition for contact transmission
(nonocular) for use in smallpox vaccine adverse event
monitoring and response
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Postvaccinial Central Nervous System Disease
Another rare adverse reaction is postvaccinial central ner-
vous system (CNS) disease such as postvaccinial encephalitis
(PVE) or encephalomyelitis (PVEM). CNS disease after small-
pox vaccination is most common among infants aged <12
months (10) (Box 9). Clinical symptoms reflect cerebral or
cerebellar dysfunction with headache, fever, vomiting, altered
mental status, lethargy, seizures, and coma. CNS lesions have
been reported in the cerebrum, medulla, and spinal cord. Both
PVE and PVEM have been described (11,25). No clinical cri-
teria, radiologic findings, or laboratory tests exist that are di-
agnostic for PVE or PVEM. Other infectious or toxic etiolo-
gies should be considered and ruled out; the diagnosis of PVE
or PVEM after smallpox vaccination is a diagnosis of exclusion.
Cardiac
Myo/pericarditis
An adverse reaction previously reported but not well de-
scribed is myo/pericarditis. During 1950–1970, both myo-
carditis and pericarditis were reported after smallpox
vaccination in Europe and Australia, where the vaccinia strains
Ocular vaccinia is the appearance of lesions suspicious
for vaccinia in or near the eye in a vaccinee (or close con-
tact of a vaccinee) up to 10 days after the period beginning
with initial vaccinia exposure through final resolution and
scarring of lesions at vaccination site or exposure site, to
include periocular* involvement, lid involvement (blephari-
tis†), conjunctival involvement (conjunctivitis§), and/or
corneal involvement (keratitis¶).
Case definition for ocular vaccinia
A  suspected case of ocular vaccinia is defined as the new
onset of erythema or edema of the conjunctiva (conjunc-
tivitis), eyelid (blepharitis), or periocular area or inflamma-
tion of the cornea (keratitis) in a recent vaccinee (or close
contact of vaccinee) that cannot be ascribed to another ocu-
lar diagnosis
and
• Temporal criteria of
— onset after vaccinia exposure but not more than 10
days after the period beginning with initial vaccinia
exposure through final resolution and scarring of le-
sions at vaccination site or exposure site
or
— onset during the presence of visible vaccinia lesions
before scab separation.
A probable case of ocular vaccinia is the presentation
in or near the eye of lesions consistent with vaccinia infec-
tion to include formation of vesicles that progress to pus-
tules that umbilicate and indurate in a manner similar to a
normal vaccinia reaction (Note: see exceptions/differences
to conjunctival and cornea clinical presentation footnotes
§ and ¶)
and
• Temporal criteria of
— onset after vaccinia exposure but not more than 10
days after the period beginning with initial vaccinia
exposure through final resolution and scarring of
lesions at vaccination site or exposure site
or
— onset during the presence of visible vaccinia lesions
before scab separation.
A confirmed case of ocular vaccinia meets the criteria
as a probable or suspected case of ocular vaccinia with
laboratory evidence of vaccinia infection (testing lesions
on or near the eye). Laboratory evidence includes
— positive test results for vaccinia polymerase chain
reaction assay or antigen detection techniques (e.g.,
direct fluorescent antibody)
or
— demonstration of vaccinia virus by culture.
BOX 4. Surveillance case definition for ocular vaccinia for use in smallpox vaccine adverse event monitoring and response
* Periocular involvement (generally above the brow or below the inferior orbital rim) Papules, vesicles, or pustules not involving the ocular adnexa, lids, lid
margins, or canthi.
† Blepharitis: (lid involvement): Mild — few pustules, mild edema, and no fever; Severe — pustules, edema, hyperemia, lymphadenopathy (preauricular or
submandibular), cellulitis, and fever.
§ Conjunctivitis (involvement of membrane that lines inner surface of the eyelid and exposed surface of the eyeball, excluding the cornea): Conjunctiva might be
inflamed (red) with serous or mucopurulent discharge if lesions involve the conjunctiva or cornea. Symptoms of ocular irritation (foreign body sensation)
might be present with onset of erythema. Conjunctival lesions typically form vesicles that rapidly ulcerate and form raised “moist appearing” white lesions
(rather than pustules that scab) before final resolution: Mild — mild hyperemia or edema, no membranes or focal lesions; Severe — marked hyperemia, edema,
membranes, focal lesions, lymphadenopathy (preauricular and/or submandibular), and fever.
¶ Keratitis (corneal involvement): Corneal lesions might present as a grey-appearing superficial punctuate keratitis that might later coalesce to form a geographic
epithelial defect resembling herpes simplex keratitis. Stromal corneal lesions might present as small subepithelial opacities resembling those observed in
epidemic keratoconjunctivitis, might be associated with epithelial defect, and might progress to corneal haze/clouding: Mild — grey epitheliitis, no epithelial
defect, and no stromal haze or infiltrate (cloudy cornea); Moderate — epithelial defect; Severe — ulcer, stromal haze, or infiltrate.
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Generalized vaccinia (GV) is a disseminated vesicular or
pustular rash appearing anywhere on the body >4 days af-
ter smallpox vaccination and might be accompanied by fe-
ver. GV also can appear as a regional form that is
characterized by extensive vesiculation around the vaccina-
tion site or as an eruption localized to a single body region.
The skin lesions of GV are thought to contain virus spread
by the hematogenous route. Primary vaccinees are at higher
risk for GV than revaccinees. GV is usually self-limited
among immunocompetent hosts. Vaccinia immune globu-
lin (VIG) might be beneficial in the rare case where an im-
munocompetent person appears systemically ill. GV is often
more severe among persons with underlying immunodefi-
ciency, and these patients might benefit from early inter-
vention with VIG.
Notes:
1) Systemic symptoms might be present.
2) At early onset of some cases, skin lesions might be
macules or slightly elevated papules; in late cases,
lesions might have developed scabs.
3) History or clinical signs of eczema/atopic dermatitis
or Darier’s disease or severe illness should prompt
evaluation for eczema vaccinatum.
4) Presence of acute or chronic exfoliative, erosive, or
blistering skin disease (e.g., acute burn and
epidermolytic hyperkeratosis) should prompt con-
sideration of multiple inadvertent inoculations.
5) A vaccinial skin eruption characterized by grouped
vesicles or pustules close to or surrounding the vac-
cination site but do not appear to be satellite lesions
(e.g., on the basis of the presence of a large number
of lesions and evidence that the lesions are caused by
hematogenous spread of vaccinia) might constitute
a regional form of generalized vaccinia.
Case definition for generalized vaccinia
A probable case of generalized vaccinia occurs in per-
sons recently vaccinated or in a close contact of a recent
vaccinee and meets the following criteria:
• a vesicular or pustular eruption at one or more body
areas distant from the vaccination site or inadvertent
inoculation site,
• skin eruption occurring approximately 4–19 days
after smallpox vaccination or contact with someone vac-
cinated against smallpox,
• lesions follow approximately the same morphologic
progression as a primary vaccination site (i.e., papule,
vesicle, pustule, scab, and scar),
• unlikely that autoinoculation accounts for skin
eruption, and
• other likely etiologies have been excluded.
A confirmed case of generalized vaccinia can occur in a
recent vaccinee, a known close contact of a recent vac-
cinee, or someone with no known contact but who other-
wise meets the criteria for a probable case and no laboratory
evidence of vaccinia infection (on the basis of testing skin
lesions distal from vaccination site in a vaccinee or distal
to likely inoculation site [if identifiable]) exists in a close
contact of a known vaccinee or in a patient who is not
known to be a close contact.
• Laboratory evidence of vaccinia infection includes
— demonstration of vaccinia virus by culture
or
— histopathologic examination shows typical orthopox
cytopathic changes, and either polymerase chain re-
action assay or antigen detection techniques (e.g.,
direct fluorescent antibody) revealing vaccinia or
electron microscopy of biopsy specimens revealing
orthopox virus are strongly suggestive of infection
with vaccinia and should be confirmed by subse-
quent culture.
BOX 5. Surveillance case definition for generalized vaccinia after smallpox vaccination for use in smallpox vaccine adverse
event monitoring and response
used are considered more reactogenic than the New York City
Board of Health (NYCBOH) vaccine used in the United States
(26–28). In the United States, six cases were reported before
the resumption of smallpox vaccination in late 2002 (29–34).
Findings from the DHHS and DoD smallpox programs sup-
port a causal relation between smallpox vaccination with the
NYCBOH strain and myo/pericarditis (35–38). Myo/peri-
carditis refers to inflammatory disease of the myocardium,
pericardium, or both. The clinical presentation of inflamma-
tory heart disease can include pain, dyspnea, and palpitations
that range from subtle to severe. Results of specific cardiac
diagnostic testing are variable. The case definition (Box 10)
was designed to include the spectrum of abnormalities found
in inflammatory heart disease (39).
Dilated Cardiomyopathy
An adverse event noted in temporal association to smallpox
vaccination but not demonstrated to be linked etiologically
to smallpox vaccination is dilated cardiomyopathy (DCM).
DCM is a known sequelae of viral myocarditis and can present
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weeks to months after acute infection (40). Although DCM
has not been reported in association with vaccinia vaccina-
tion, three DCM cases with symptom onset after smallpox
vaccination were identified among DHHS vaccinees
(12,41,42). The causal relation between smallpox vaccination
and these cases of DCM is unclear. However, because vac-
cinia might induce myo/pericarditis and DCM is a rare but
recognized outcome of viral myocarditis, an etiologic associa-
tion between the occurrence of DCM after smallpox vaccina-
tion is biologically plausible. The case definition for DCM
should be used for surveillance in the context of smallpox pre-
paredness programs (Box 11).
Eczema vaccinatum (EV) is a localized or generalized
papular, vesicular, pustular, or erosive rash syndrome that
can occur anywhere on the body, with a predilection for
areas currently or previously affected by atopic dermatitis
lesions. Persons with a history of atopic dermatitis are at
highest risk for EV. Onset of the characteristic lesions can
be noted either concurrently with or shortly after the de-
velopment of the local vaccinial lesion in vaccinees. EV cases
resulting from secondary transmission usually appear with
skin eruptions approximately 5–19 days after the suspected
exposure. EV lesions follow the same dermatologic course
(progression) as the vaccination site in a vaccinee, and
confluent or erosive lesions can occur. The rash is often
accompanied by fever and lymphadenopathy, and affected
persons are frequently systemically ill. EV tends to be most
severe among first-time vaccinees, young children, and un-
vaccinated close contacts of vaccinees. Before the availabil-
ity of vaccinia immune globulin (VIG), this condition had
a high mortality. Establishing the diagnosis early and treat-
ing with VIG is crucial in reducing mortality.
Notes:
1) Although a history consistent with eczema/atopic der-
matitis or Darier’s disease (i.e., keratosis follicularis)
is included in the surveillance definition for EV, cli-
nicians evaluating vaccinees or close contacts of re-
cent vaccinees with a presentation consistent with
EV who do not report having one of these dermato-
logic conditions should still consider EV as a clinical
diagnosis and assess for treatment with VIG.
2) Lesions of EV are in approximately the same stage of
morphologic development as each other and progress.
Case definition for eczema vaccinatum
A probable case of EV occurs in persons recently vacci-
nated or in a known close contact of a recent vaccinee and
meets the following criteria:
• a history of or current exfoliative skin condition consis-
tent with a diagnosis of eczema/atopic dermatitis or
Darier’s disease;
and
BOX 6. Surveillance case definition for eczema vaccinatum after smallpox vaccination for use in smallpox vaccine adverse
event monitoring and response
• multiple skin lesions that developed
— in a vaccinated person concurrently or soon after
lesion at vaccination site or in a close contact of a
recent vaccinee up to 3 weeks after exposure, if time
of relevant exposure is known,
— are distant from the vaccination or likely inocula-
tion site (i.e., are unlikely to be satellite lesions),
and
— are or have become vesicular/pustular sometime
during their evolution (i.e., do not remain macular
or papular). Erosive or ulcerative lesions might be
observed;
and
• other likely etiologies have been excluded such as ec-
zema herpeticum (which can be particularly difficult
to distinguish), smallpox, chickenpox, disseminated
herpes zoster, or pustular (bacterial) impetigo.
A confirmed case of EV can occur in a recent vaccinee,
a known close contact of a recent vaccinee, or someone
with no known contact but who otherwise meets the cri-
teria for a probable case and laboratory evidence of vac-
cinia infection exists (on the basis of testing skin lesions
distal from vaccination site in a vaccinee or distal to likely
inoculation site, if identifiable) in a close contact of a
known vaccinee or in a patient who is not known to be a
close contact.
• Laboratory evidence of vaccinia infection includes
— demonstration of vaccinia virus by culture
or
— polymerase chain reaction assay or antigen detec-
tion techniques (e.g., direct fluorescent antibody)
revealing vaccinia, histopathologic examination
showing typical orthopox cytopathic changes, and
electron microscopy of biopsy specimens revealing
orthopox virus are strongly suggestive of infection
with vaccinia and should be confirmed by subse-
quent culture.
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Case Classification
Case definitions are designed to identify the entities under
surveillance, not to define the certainty of an etiologic rela-
tion between the entities under surveillance and vaccinia ex-
posure. Thus, cases are classified as suspected if they have
compatible clinical features but either further investigation is
required or investigation of the case did not provide enough
supporting evidence for the diagnosis. Cases are classified as
probable if they have compatible clinical features and infor-
mation is supportive of, but not definitive for, the diagnosis.
Cases are classified as confirmed if pathognomonic findings
or other evidence definitely supporting the diagnosis is docu-
mented. In certain instances, confirmation is made on the
basis of verification of the presence of vaccinia or of orthopox
virus DNA by culture or polymerase chain reaction (PCR)
detection. Confirmation also might be determined on the basis
of other evidence in instances in which vaccinia presence is
not a pathognomonic feature of the entity under surveillance
(e.g., myocarditis or pericarditis, both of which are believed
to be an immune-mediated response to vaccination rather than
mediated through vaccinia viral infection).
Classification of certain smallpox adverse vaccine reactions
can be confounded by lack of information or the absence of
pathognomonic findings. This is illustrated by the limited un-
Progressive vaccinia (PV) refers to continued vaccinia vi-
rus replication with progressive infection of skin surround-
ing the vaccination site or inadvertent inoculation site and
sometimes the occurrence of secondary metastatic lesions
in a person with underlying immune deficit (humoral or
cellular). The condition is rare, severe, and often lethal. The
description of the vaccination site lesion is usually that of a
necrotic lesion; however, this is not the only presentation
described with PV. Lesions can appear “clean,” fungated,
piled-up, well-demarcated, or have bacterial superinfection.
Case definition for progressive vaccinia
A suspected case of PV occurs in persons recently vacci-
nated or in a known close contact of a recent vaccinee and
meets the following criteria:
• have a known or suspected depressed or defective im-
mune system (suspicion might arise as result of clinical
suspicion of PV);
and
• have a vaccination site lesion or inadvertent inoculation
site with one of the following criteria:
— no or minimal inflammatory response around lesion
associated with a nonhealing or enlarging vaccina-
tion lesion,
— progressive expansion at or after 15 days of vaccina-
tion, or
— Failure to heal or failure of lesion to regress at or
after 15 days of vaccination;
and
• other likely etiologies (e.g., bacterial superinfection) have
been excluded.
A probable case of PV occurs in persons recently vacci-
nated or in a known close contact of a recent vaccinee and
meets the following criteria:
• a known or suspected depressed or defective immune
system
and
• a vaccination site lesion or inadvertent inoculation site
with one of the following criteria:
— no or minimal inflammatory response around le-
sion associated with a nonhealing or enlarging vac-
cination lesion,
— progressive expansion at or after 21 days of vacci-
nation, or
— failure to heal or failure of lesion to regress at or
after 21 days of vaccination;
and
• other likely etiologies (e.g., bacterial superinfection)
have been excluded.
A confirmed case of PV can occur in a recent vaccinee,
a known close contact of a recent vaccinee, or someone
with no known contact but who otherwise meets the cri-
teria for a suspected case and laboratory evidence of vac-
cinia infection (on the basis of testing skin lesions at least
15 days after vaccination or likely time of inoculation in a
close contact of a recent vaccinee or in persons with no
known contact with a vaccinee) exist
Laboratory evidence of vaccinia infection include
• demonstration of vaccinia virus by culture
or
• histopathologic examination showing typical orthopox
cytopathic changes, and either polymerase chain reac-
tion assay or antigen detection techniques (e.g., direct
fluorescent antibody) revealing vaccinia or electron mi-
croscopy of biopsy specimens revealing orthopox virus
are strongly suggestive of infection with vaccinia and
should be confirmed by subsequent culture.
BOX 7. Surveillance case definition for progressive vaccinia for use in smallpox vaccine adverse event monitoring and response
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Fetal vaccinia is a rare but serious complication result-
ing from vaccinia infection in utero that can occur in
any trimester of pregnancy. It has been characterized by
the presence of multiple skin lesions, including macules,
papules, vesicles, pustules, scars, ulcers, areas of macera-
tion, and epidermolysis (blisters or bullae). When fetal
vaccinia occurs, the outcome is usually fetal death, still-
birth, or premature birth of a neonate that dies shortly
after birth. Survival of babies with apparent in utero in-
fection such as scarring has also been described. Vac-
cinia infection in products of conception occurs rarely.
Case definition for fetal vaccinia
A suspected case of fetal vaccinia is the presence of
any skin lesion in a fetus or newborn exposed to vac-
cinia virus in utero and no other attributable cause.
A probable case of fetal vaccinia is the presence of
multiple skin lesions that might include macules, pap-
ules, vesicles, pustules, scars, ulcers, areas of maceration,
or epidermolysis (blisters/bullae) in a fetus or newborn
exposed to vaccinia in utero and no other attributable
cause.
A confirmed case of fetal vaccinia meets the criteria
for a probable case and has laboratory evidence for vac-
cinial infection:
Laboratory criteria for diagnosis includes
• positive test results for vaccinia virus by polymerase
chain reaction assay or antigen detection techniques
(e.g., direct fluorescent antibody), or
• demonstration of vaccinia virus by culture.
Vaccinia infection: Fetus, newborn, or product of con-
ception with laboratory evidence of infection and with-
out any clinical symptoms or signs.
BOX 8. Surveillance case definition for fetal vaccinia for use
in smallpox vaccine adverse event monitoring and response
derstanding of the vaccinia virus’ pathogenesis and the rel-
evance of vaccinia testing in conditions such as postvaccinial
CNS diseases and fetal vaccinia. No large-scale study examin-
ing the cerebral spinal fluid (CSF) of smallpox vaccinees ex-
ists; therefore, the significance of the presence or absence of
vaccinia neutralizing antibodies or vaccinia virus recovered
from the CSF of a vaccinee with CNS findings is not fully
understood. Testing for the presence or absence of vaccinia
virus cannot confirm or refute a smallpox vaccine-associated
etiology for these conditions. Conversely, the inability to re-
cover vaccinia virus from burnt-out lesions from an infant
exposed to vaccinia in utero and born with skin lesions com-
patible with fetal vaccinia does not mean that intrauterine
infection did not occur. To address these limitations, the sus-
pected category for these adverse reactions allows a clinically
compatible case with indeterminate or no testing to remain
under consideration.
Vaccinia Laboratory Diagnostics
The smallpox vaccine is made from live vaccinia virus, a
species of the Orthopoxvirus genus, and protects against small-
pox disease. It does not contain the related Orthopoxvirus
variola, which is the causative agent of smallpox disease (25).
When evaluating a reported adverse event after smallpox vac-
cination, standard laboratory testing should be conducted to
rule out other infections, including viral infections (e.g., her-
pes zoster, varicella, enteroviruses, and herpes simplex). During
an outbreak of other orthopoxviruses (e.g., monkeypox and
smallpox), specific testing also should be completed for these
viruses.
Laboratory testing for vaccinia is still largely a research tool
assisting the evaluation, diagnosis, and treatment of adverse
reactions after smallpox vaccination. Testing is available
through the Laboratory Response Network (LRN) (43), which
can be accessed through state and local health departments
with confirmatory testing at CDC. Diagnostic techniques that
can aid in the detection of vaccinia include electron micros-
copy (EM), viral culture, and PCR (17). Although these tests
can identify orthopoxviruses, only certain PCR tests or biologic
characterization of viral growth on chick chorioallantoic
membrane specifically identifies the presence of vaccinia
virus. Positive results for EM, PCR, and viral culture should
be interpreted with caution. EM or culture results compatible
with orthopox virus and presumed to be vaccinia might be
another zoonotic orthopox virus or, in the worst case scenario,
variola itself. Experience with vaccinia diagnostics is limited.
Molecular contamination resulting in false-positive PCR re-
sults can occur. Therefore, use of appropriate controls is es-
sential. PCR techniques, which test for orthopoxvirus nucleic
acid presence, at LRN have undergone multicenter validation
studies, and these data along with clinical experience with these
assays is being compiled to enable the U.S. Food and Drug
Administration to review the test reagents and assay for wider
diagnostic use (17). Serologic testing of single serum samples
for vaccinia is of limited value because it cannot discern exist-
ing immunity from recent infection. Testing of paired acute
and convalescent sera antibody titers is rarely available during
initial assessment of a suspected vaccinia adverse event (17).
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Postvaccinial central nervous system disease is an inflamma-
tion of the parenchyma of the central nervous system after
smallpox vaccination. When the inflammation occurs in the
brain it is called “encephalitis,” and when it occurs in the spi-
nal cord it is called “myelitis.” Confirmation of diagnosis is
made only on the basis of the demonstration of central ner-
vous system (CNS) inflammation by histopathology or
neuroimaging, but might be suggested by clinical features.*
Case definition for encephalitis
A suspected case of encephalitis is defined as the presence
of the acute onset of
• encephalopathy (e.g., depressed or altered level of conscious-
ness, lethargy, or personality change lasting >24 hours)
• clinical evidence suggestive of cerebral inflammation to in-
clude one of the following:
— fever (temperature >100°F [>38°C]) or hypothermia
(temperature <95°F [<35°C]),
— meningismus (i.e., nuchal rigidity and photo/
phonophobia),
— cerebrospinal fluid (CSF) pleocytosis (>5 white blood
cells/mm3),
— presence of focal neurologic deficit,
— electroencephalography findings consistent with
encephalitis,
— neuroimaging findings on magnetic resonance imaging
consistent with acute inflammation (with or without
meninges) or demyelination of the nervous system, or
— seizures (either new onset or exacerbation of previously
controlled seizures);
and
• no alternative (investigated) etiologies are found for pre-
senting sign and symptoms.
A probable case of encephalitis is defined by the acute onset
of
• encephalopathy as outlined for a suspected case,
and
• two or more of the criterion listed for suspected encepha-
litis as clinical evidence suggestive of cerebral inflammation,
and
• no alternative (investigated) etiologies are found for pre-
senting sign and symptoms.
A confirmed case of encephalitis is defined as
• demonstration of acute cerebral inflammation (with or
without meninges) or demyelination by histopathology
and
• no alternative (investigated) etiologies are found for pre-
senting sign and symptoms.
Case definition for acute myelitis
A suspected case of myelitis is defined as presence of the
acute onset of
• myelopathy (development of sensory, motor, or autonomic
dysfunction attributable to the spinal cord, including
upper- and lower-motor neuron weakness, sensory level,
and bowel or bladder dysfunction);
and
• additional evidence suggestive of spinal cord inflamma-
tion, to include one of the following:
— fever (temperature >100ºF [>38ºC]) or hypothermia
(temperature <95°F [<35°C]),
— CSF pleocytosis (>5 white blood cells/mm3),
— presence of focal neurologic deficit,
— electromyographic (EMG) studies suggestive of cen-
tral (spinal cord) dysfunction, or
— neuroimaging findings on MRI demonstrating acute
inflammation (with or without meninges) or demy-
elination of the spinal cord,
and
• no alternative (investigated) etiologies are found for pre-
senting sign and symptoms.
A probable case of myelitis is defined by the acute onset of
• myelopathy as outlined for a suspected case,
and
• two or more of the criterion listed for suspected myelitis
as evidence suggestive of spinal cord inflammation,
and
• no alternative (investigated) etiologies are found for pre-
senting sign and symptoms.
A confirmed case of myelitis is defined by
• demonstration of acute spinal cord inflammation (with
or without meninges) or demyelination by histopathology,
and
• no alternative (investigated) etiologies are found for pre-
senting sign and symptoms.
Note: Cases fulfilling the criteria for both encephalitis and
myelitis in any category would be classified as
encephalomyelitis.
BOX 9. Surveillance case definition for postvaccinial central nervous system disease after smallpox vaccination for use in
smallpox vaccine adverse event monitoring and response
* Some cases of postvaccinial encephalomyelitis might be caused by direct infection of the CNS by vaccinia virus, resulting in acute cytotoxic neuronal damage and
inflammation. However, laboratory evidence of virus replication is lacking in the majority of cases and might be attributable to immunopathological mechanisms instead.
In the majority of cases, histopathologic findings similar to other “postinfectious” encephalitides are found, suggestive of an inflammatory demyelinating condition (acute
disseminated encephalitis/encephalomyelitis [ADEM]). The distinction between these two pathologic mechanisms might be difficult to make clinically in the early stages
of illness. A diagnosis of ADEM might be favored by a longer interval of onset after vaccination; magnetic resonance imaging findings of multifocal areas of increased signal
on T2, fluid attenuation inversion recovery, and diffusion weighted imaging sequences, suggestive of acute demyelination; and an absence of CSF pleocytosis.
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Conclusions
Surveillance case definitions rely on a constellation of clini-
cal, laboratory, and epidemiologic criteria for classification.
They are not intended to replace clinical judgment and should
not be used to direct individual patient care, assess causality,
or determine disability compensation or reimbursement for
medical care. The definitions have been developed specifically
for the surveillance of adverse events during the voluntary
DHHS civilian smallpox preparedness and response program
and might not apply to vaccinees in other settings (e.g., clini-
BOX 10. Surveillance case definition for myo/pericarditis for use in smallpox vaccine adverse event monitoring and response
Myo/pericarditis
Myo/pericarditis is defined as a spectrum of disease caused
by inflammation of the myocardium and/or pericardium.
Patients might have symptoms and signs consistent with
myocarditis, pericarditis, or both. For the purpose of sur-
veillance reporting, patients with myocarditis or pericardi-
tis will be reported as having myo/pericarditis. These
categories are intended for surveillance purposes and not
for use in individual diagnosis or treatment decisions.
Case definition for acute myocarditis
A suspected case of acute myocarditis is defined by the
following criteria and the absence of evidence of any other
likely cause of symptoms or findings below:
• presence of dyspnea, palpitations, or chest pain of prob-
able cardiac origin in a patient with either one of the
following:
— electrocardiogram (ECG) abnormalities beyond nor-
mal variants, not documented previously, including
– ST-segment or T-wave abnormalities,
– paroxysmal or sustained atrial or ventricular
arrhythmias,
– AV nodal conduction delays or intraventricular
conduction defects, or
– continuous ambulatory electrocardiographic
monitoring that detects frequent atrial or ventricu-
lar ectopy
or
— Evidence of focal or diffuse depressed left-ventricu-
lar (LV) function of indeterminate age identified by
an imaging study (e.g., echocardiography or radio-
nuclide ventriculography).
A probable case of acute myocarditis, in addition to the
above symptoms and in the absence of evidence of any other
likely cause of symptoms, has one of the following:
• elevated cardiac enzymes, specifically, abnormal levels
of cardiac troponin I, troponin T, or creatine kinase myo-
cardial band (a troponin test is preferred);
• evidence of focal or diffuse depressed LV function iden-
tified by an imaging study (e.g., echocardiography or
radionuclide ventriculography) that is documented to
be of new onset or of increased degree of severity (in
the absence of a previous study, findings of depressed
LV function are considered of new onset if, on follow-
up studies, these findings resolve, improve, or worsen);
or
• abnormal result of cardiac radionuclide imaging (e.g.,
cardiac MRI with gadolinium or gallium-67 imaging)
indicating myocardial inflammation.
A case of acute myocarditis is confirmed if histopatho-
logic evidence of myocardial inflammation is found at
endomyocardial biopsy or autopsy.
Case definition for acute pericarditis
A suspected case of acute pericarditis is defined by the
presence of
• typical chest pain (i.e., pain made worse by lying down
and relieved by sitting up and/or leaning forward) and
• no evidence of any other likely cause of such chest pain.
A probable case of acute pericarditis is a suspected case
of pericarditis, or a case in a person with pleuritic or other
chest pain not characteristic of any other disease, that, in
addition, has one or more of the following:
• pericardial rub, an auscultatory sign with one to three
components per beat,
• ECG with diffuse ST-segment elevations or PR de-
pressions without reciprocal ST depressions that are
not previously documented, or
• echocardiogram indicating the presence of an abnor-
mal collection of pericardial fluid (e.g., anterior and
posterior pericardial effusion or a large posterior peri-
cardial effusion alone).
Note: A case of acute pericarditis is confirmed if histo-
pathologic evidence of pericardial inflammation is evident
from pericardial tissue obtained at surgery or autopsy.
Surveillance Results and Outcome
The voluntary DHHS civilian smallpox preparedness and
response program established adverse event case monitoring
capacity and response within CDC and state and local health
departments. Data collected were derived from the standard-
ized case definitions and enabled rapid classification, report-
ing, and the ability to compare adverse reaction surveillance
data from various sources. Accurate classification of vaccinia
adverse reactions is necessary for appropriate use of VIG and
cidofovir for the treatment of select vaccinia reactions.
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cal trials). These surveillance case definitions might not apply
to the international community, which administers non-
NYCBOH vaccinia strains and faces different considerations
in health-care use and surveillance systems. These case defini-
tions are a component of a dynamic surveillance process. As
knowledge and experience increase, they might be modified
or improved. Ongoing input from health-care providers and
health departments are important for the successful imple-
mentation and use of these case definitions.
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Dilated cardiomyopathy (DCM) is defined by the
World Health Organization as a disease of the heart
muscle characterized by dilatation and impaired con-
traction of the left ventricle or both ventricles.  It might
be idiopathic, familial/genetic, viral, and/or immune,
alcoholic/toxic, or associated with recognized cardiovas-
cular disease in which the degree of myocardial dysfunc-
tion is not explained by the abnormal loading conditions
or the extent of ischemic damage. Histology is nonspe-
cific. Presentation is usually with heart failure, which is
often progressive. Arrhythmias, thromboembolism, and
sudden death are common and can occur at any stage.
Despite full cardiac workup, the etiology of DCM often
cannot be determined. Because other viruses are known
to cause DCM, the occurrence of DCM after smallpox
vaccination is plausible, although not previously de-
scribed. Because histologic findings of DCM are often
nonspecific, endomyocardial biopsy is not likely to con-
firm an etiologic role for vaccinia but might rule out
other known etiologies of DCM (e.g., sarcoidosis and
amyloidosis). The following case definition describes the
structural and functional cardiac criteria and clinical
conditions required to define a case of DCM for use in
the smallpox adverse events monitoring and response
activity.
Case definition for dilated cardiomyopathy after
smallpox vaccination
Smallpox vacinees are defined as having DCM if they
meet all of the following criteria:
• cardiac muscle dysfunction exists, characterized by
ventricular dilatation (e.g., left ventricular end-
diastolic dimension >55 mm) and impaired contrac-
tion of one or both ventricles (e.g., left ventricular
ejection fraction <0.45);
• no evidence of DCM or congestive heart failure be-
fore vaccination, either by history (e.g., dyspnea on
exertion and fatigue) or by cardiac evaluation, in-
cluding chest radiography or echocardiography if
available; and
• no other cardiac or noncardiac disease can account
for the symptoms or abnormalities present. If an-
other cardiac disease coexists, it is not sufficient to
cause the degree of myocardial dysfunction present
(e.g., ischemic or valvular heart disease or long-
standing hypertension). No other etiology of DCM
can be determined, such as alcohol or cocaine use,
hypertension, morbid obesity, or other causes.
BOX 11. Surveillance case definition for dilated
cardiomyopathy for use in smallpox vaccine adverse event
monitoring and response
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Goal and Objectives
This MMWR provides surveillance guidelines for adverse reactions after smallpox vaccination. The case definitions and classifications were developed by CDC, in
conjunction with staff of the Department of Defense, the Advisory Committee on Immunization Practices-Armed Forces Epidemiological Board Smallpox Vaccine
Safety Working Group, and smallpox subject-matter experts. The goal of this report is to provide the case definitions used to classify reported adverse events after
smallpox vaccination during the 2003 Department of Health and Human Services (DHHS) smallpox vaccination program. Upon completion of this educational
activity, the reader should be able to 1) identify the known adverse reactions to smallpox vaccination and be familiar with their case definitions, 2) recognize the
importance of reporting adverse events after smallpox vaccination, 3) describe those adverse reactions after smallpox vaccination that require laboratory confirmatory
testing for vaccinia, and 4) describe when and how to report all adverse events after vaccination.
To receive continuing education credit, please answer all of the following questions.
1. Which of the following can fulfill the criteria for exposure to vaccinia?
A. Smallpox vaccination.
B. Close contact with a recent smallpox vaccinee.
C. Intrauterine exposure.
D. A and B are correct.
E. All of the above.
2. Normal vaccination reactions are often confused with…
A. superinfection of the vaccination site.
B. generalized vaccinia.
C. eczema vaccinatum.
D. none of the above.




D. All of the above.
4. When evaluating a reported adverse event after smallpox vaccination,
standard laboratory testing should include…
A. herpes zoster virus.
B. enteroviruses.
C. herpes simplex virus.
D. other orthopox viruses during specific outbreaks.
E. all of the above.
5. Eczema vaccinatum and progressive vaccinia are adverse reactions
after smallpox vaccination and…
A. thought to be associated with replicating vaccinia virus recovered from
skin lesions.
B. are benign and self-limited.
C. usually require vaccinia immune globulin (VIG).
D. often can be prevented by screening persons before smallpox
vaccination.
E. A, C, and D.





D. all of the above.
7. Surveillance case definitions for adverse events after smallpox
vaccination during the DHHS smallpox preparedness and response
program can…
A. enable classification and reporting of adverse events after smallpox
vaccination.
B. direct patient care.
C. assess causality.
D. determine disability compensation.
E. A and C.








9. Ocular vaccinia accounts for the majority of inadvertent inoculations.
A. True.
B. False.
10. Without standardized case definitions, health-care providers often
apply different criteria for reporting similar cases.
A. True.
B. False.






12. I plan to use these recommendations as the basis for …(Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
13. Overall, the length of the journal report was…
A. much too long.
B. a little too long.
C. just right.
D. a little too short.
E. much too short.




































































































































































































































































































































































































































































































































14. After reading this report, I am confident I can identify the known







15. After reading this report, I am confident I recognize the importance of






16. After reading this report, I am confident I can describe those adverse
reactions after smallpox vaccination that require laboratory






17. After reading this report, I am confident I can describe when and how













19. The boxes and table (instructional strategies) used in this report
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Correct answers for questions 1–10.
1. E; 2. A; 3. D; 4. E; 5. E; 6. D; 7. A; 8. E; 9. A; 10. A.


















24. The availability of continuing education credit influenced my












26. Do you feel this course was commercially biased? (Indicate yes or no;
if yes, please explain in the space provided.)
A. Yes.
B. No.
27. How did you learn about the continuing education activity?
A. Internet.
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